A Phase 2 interventional study of Ravulizumab and Placebo in Lupus Nephritis and Immunoglobulin A Nephropathy, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 64 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 28th largest by enrollment of the 100 interventional ones that give a count, is one of 2 that started in 2021, is one of 34 in phase 2, and was the 51st registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
This study consists of a 6-week Screening Period, 26-week Initial Evaluation Period, a 24-week Extension Period, and a 36-week post-treatment Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Common to both disease cohorts:
For LN cohort:
For IgAN cohort:
Exclusion Criteria:
Common to both disease cohorts:
For IgAN cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
Drug: Ravulizumab · Other: Background Therapy
Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
Drug: Placebo · Other: Background Therapy
Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
Drug: Ravulizumab · Other: Background Therapy
Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
Drug: Ravulizumab · Drug: Placebo · Other: Background Therapy
Dosages (loading and maintenance) will be based on the participant's body weight.
Also known as: Ultomiris
Dosages (loading and maintenance) will be based on the participant's body weight.
Participants will receive background therapy consistent with the standard of care.
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections)
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
Time frame: Baseline, Week 26
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections)
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
Time frame: Baseline, Week 26
IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections)
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
Time frame: Baseline, Week 50
LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections)
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
Time frame: Baseline, Week 50
IgAN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints.
Time frame: Baseline to Week 26 and Week 50
LN Cohort: Percentage of Participants With > 30% and > 50% Reduction in Proteinuria at Week 26 and Week 50 Compared to Baseline Assessed Using 24-hour Urine Collections
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints.
Time frame: Baseline to Week 26 and Week 50
IgAN Cohort: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 and Week 50
Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in milliliters/minute/1.73 meters squared (mL/min/1.73 m\^2). Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.
Time frame: Baseline, Week 26 and Week 50
LN Cohort: Change From Baseline in eGFR at Week 26 and Week 50
Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in mL/min/1.73 m\^2. Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.
Time frame: Baseline, Week 26 and Week 50
IgAN Cohort: Change From Baseline in Serum Complement Component 3 (C3) and Complement Component 4 (C4) Concentrations at Week 26 and Week 50
Time frame: Baseline, Week 26 and Week 50
LN Cohort: Change From Baseline in Serum C3 and C4 Concentrations at Week 26 and Week 50
Time frame: Baseline, Week 26 and Week 50
LN Cohort: Percentage of Participants Meeting the Criteria for Complete Renal Response (CRR)
The CRR was defined as meeting all 3 of the following criteria: - UPCR ≤0.5 gram/gram (g/g); - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal systemic lupus erythematosus (SLE) flare, or suboptimal response.
Time frame: Week 26 and Week 50
LN Cohort: Percentage of Participants Meeting the Criteria for Partial Renal Response (PRR)
The PRR was defined as meeting all 3 of the following criteria: - decrease of UPCR \>50% from baseline; - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.
Time frame: Week 26 and Week 50
LN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples
Time frame: Baseline through Week 50
LN Cohort: Percentage of Participants Achieving Corticosteroid Taper to 7.5 Milligrams (mg)/Day
A corticosteroid taper was carried out per protocol at the clinical discretion of the investigator.
Time frame: Week 14, Week 26, and Week 50
LN Cohort: Percentage of Participants With Renal Flare
Renal flare was determined in the opinion of the investigator and additional protocol-specified criteria. For participants who achieved a CRR, a renal flare was the reproducible recurrence of proteinuria ≥1g/g. For all other participants, a renal flare was either of the following: a reproducible increase of serum creatinine \>25% higher than baseline, above the upper limit of normal (plus additional protocol-specified criteria), or a reproducible doubling of the UPCR from a 24-hour urine collection compared with the lowest previous value obtained after the first dose of study intervention.
Time frame: Baseline through Week 50
LN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare
Extrarenal SLE flare was defined as an increase in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Safety of Estrogens in Lupus Erythematosus National Assessment modification ≥4 points that was not accounted for by proteinuria, hematuria, urinary cellular casts, hypocomplementemia, or an increase in anti-double-stranded DNA antibody level. The SLEDAI-2K is an instrument that was used to assess the disease activity of extrarenal SLE flare across 18 disease descriptors. Each descriptor carried a weighted value ranging from 1-8, with the reported score calculated as the sum of these descriptors and ranging from 0 to 85. Higher scores represent increased degrees of disease activity.
Time frame: Baseline through Week 50
LN Cohort: Percentage of Participants With Treatment Failure
Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.
Time frame: Baseline through Week 50
LN Cohort: Percentage of Participants With Suboptimal Response
A suboptimal response was to be determined in the opinion of the investigator in addition to the following criterion: reproducible proteinuria ≤25% decreased compared to baseline based on UPCR on a 24-hour urine collection performed by a central laboratory.
Time frame: Baseline through Week 50
LN Cohort: Change From Baseline in Serum Albumin at Week 26 and Week 50
For the determination of serum albumin, blood samples were obtained at designated time points.
Time frame: Baseline, Week 26, Week 50
IgAN Cohort: Percentage of Participants Meeting the Criteria for Partial Remission
Partial remission was defined as mean proteinuria \<1 g/24 hours, based on two valid 24-hour urine collections obtained within 2 weeks prior to the study visit.
Time frame: Week 26 and Week 50
| Milestone | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|---|---|
| Started | 38 | 19 | 43 | 23 |
| Received at least 1 dose of study drug | 38 | 19 | 43 | 23 |
| Completed | 36 | 18 | 42 | 23 |
| Not completed | 2 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Milestone | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|---|---|
| Started | 36 | 18 | 42 | 23 |
| Completed | 34 | 17 | 41 | 23 |
| Not completed | 2 | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 0 | 0 |
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
| percentage change | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Absolute Protein (Based on 24-hour Urine Collections) | -41.9 (-50.2 to -32.0) | -16.8 (-31.8 to 1.6) |
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
| percentage change | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 26 Measured by Urine Protein to Creatinine Ratio (UPCR) (Based on 24-hour Urine Collections) | -69.7 (-79.9 to -54.5) | -67.0 (-80.8 to -43.1) |
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
| percentage change | IgAN Cohort - Ravulizumab | IgAN Cohort - Placebo |
|---|---|---|
| IgAN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by Absolute Protein (Based on 24-hour Urine Collections) | -44.8 (-55.1 to -32.1) | -45.1 (-58.0 to -28.4) |
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints. A negative change from baseline indicated a reduction in symptoms.
| percentage change | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage Change From Baseline in Proteinuria at Week 50 Measured by UPCR (Based on 24-hour Urine Collections) | -77.1 (-86.0 to -62.4) | -75.0 (-87.2 to -51.2) |
Proteinuria, the presence of excess proteins in the urine, was measured by absolute protein in grams/day derived from 24-hour urine collections obtained at designated timepoints.
| percentage of participants | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|
| Week 26: >30% Reduction | 68.3 (51.9 to 81.9) | 40.9 (20.7 to 63.6) |
| Week 26: >50% Reduction | 43.9 (28.5 to 60.3) | 18.2 (5.2 to 40.3) |
| Week 50: >30% Reduction | 63.4 (46.9 to 77.9) | 60.9 (38.5 to 80.3) |
| Week 50: >50% Reduction | 36.6 (22.1 to 53.1) | 39.1 (19.7 to 61.5) |
Proteinuria, the presence of excess proteins in the urine, was measured by UPCR in grams/gram derived from 24-hour urine collections obtained at designated timepoints.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Week 26: >30% Reduction | 50.0 (33.4 to 66.6) | 73.7 (48.8 to 90.9) |
| Week 26: >50% Reduction | 47.4 (31.0 to 64.2) | 57.9 (33.5 to 79.7) |
| Week 50: >30% Reduction | 55.3 (38.3 to 71.4) | 63.2 (38.4 to 83.7) |
| Week 50: >50% Reduction | 52.6 (35.8 to 69.0) | 47.4 (24.4 to 71.1) |
Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in milliliters/minute/1.73 meters squared (mL/min/1.73 m\^2). Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.
| mL/min/1.73 m^2 | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|
| Change at Week 26 | 0.22 (-2.30 to 2.74) | -4.51 (-7.90 to -1.11) |
| Change at Week 50 | -3.87 (-6.41 to -1.33) | -6.33 (-9.72 to -2.94) |
Changes in kidney function were monitored using measurements of eGFR and calculated based on the Chronic Kidney Disease Epidemiology Collaboration formula. Results are reported in mL/min/1.73 m\^2. Estimates of change from baseline are least-square means based on a mixed-effect model for repeated measures model that included change from baseline as the response variable, treatment as independent variable and adjusts for covariates of baseline and the stratification factor at randomization. An increase in eGFR in response to treatment indicated a reduction in symptoms.
| mL/min/1.73 m^2 | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Change at Week 26 | 11.59 ± 3.38 | 14.04 ± 4.56 |
| Change at Week 50 | 12.12 ± 3.49 | 14.83 ± 4.86 |
| grams/liter | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|
| C3: Change at Week 26 | 0.027 ± 0.2389 | -0.019 ± 0.2366 |
| C3: Change at Week 50 | -0.001 ± 0.1902 | -0.084 ± 0.1861 |
| C4: Change at Week 26 | -0.005 ± 0.0576 | -0.001 ± 0.0566 |
| C4: Change at Week 50 | -0.006 ± 0.0510 | -0.027 ± 0.0489 |
| grams/liter | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| C3: Change at Week 26 | 0.139 ± 0.2414 | 0.130 ± 0.1809 |
| C3: Change at Week 50 | 0.213 ± 0.4783 | 0.247 ± 0.2703 |
| C4: Change at Week 26 | 0.041 ± 0.0775 | 0.028 ± 0.0668 |
| C4: Change at Week 50 | 0.042 ± 0.0887 | 0.052 ± 0.0891 |
The CRR was defined as meeting all 3 of the following criteria: - UPCR ≤0.5 gram/gram (g/g); - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal systemic lupus erythematosus (SLE) flare, or suboptimal response.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Week 26 | 26.3 (13.4 to 43.1) | 21.1 (6.1 to 45.6) |
| Week 50 | 42.1 (26.3 to 59.2) | 31.6 (12.6 to 56.6) |
The PRR was defined as meeting all 3 of the following criteria: - decrease of UPCR \>50% from baseline; - eGFR \>60 mL/min/1.73 m\^2 or no eGFR reduction ≥20% from baseline; and - no treatment failure. Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Week 26 | 15.8 (6.0 to 31.3) | 36.8 (16.3 to 61.6) |
| Week 50 | 10.5 (2.9 to 24.8) | 10.5 (1.3 to 33.1) |
| days | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Time to Urine Protein to Creatinine Ratio (UPCR) < 0.5 g/g, as Measured by Spot Urine Samples | 184.0 (71.0 to NA) | 295.0 (128.0 to NA) |
A corticosteroid taper was carried out per protocol at the clinical discretion of the investigator.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Week 14 | 84.2 (68.7 to 94.0) | 94.4 (72.7 to 99.9) |
| Week 26 | 94.4 (81.3 to 99.3) | 100 (81.5 to 100) |
| Week 50 | 76.5 (58.8 to 89.3) | 82.4 (56.6 to 96.2) |
Renal flare was determined in the opinion of the investigator and additional protocol-specified criteria. For participants who achieved a CRR, a renal flare was the reproducible recurrence of proteinuria ≥1g/g. For all other participants, a renal flare was either of the following: a reproducible increase of serum creatinine \>25% higher than baseline, above the upper limit of normal (plus additional protocol-specified criteria), or a reproducible doubling of the UPCR from a 24-hour urine collection compared with the lowest previous value obtained after the first dose of study intervention.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage of Participants With Renal Flare | 13.2 (4.4 to 28.1) | 5.3 (0.1 to 26.0) |
Extrarenal SLE flare was defined as an increase in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Safety of Estrogens in Lupus Erythematosus National Assessment modification ≥4 points that was not accounted for by proteinuria, hematuria, urinary cellular casts, hypocomplementemia, or an increase in anti-double-stranded DNA antibody level. The SLEDAI-2K is an instrument that was used to assess the disease activity of extrarenal SLE flare across 18 disease descriptors. Each descriptor carried a weighted value ranging from 1-8, with the reported score calculated as the sum of these descriptors and ranging from 0 to 85. Higher scores represent increased degrees of disease activity.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage of Participants With Extrarenal Systemic Lupus Erythematosus (SLE) Flare | 2.6 (0.1 to 13.8) | 0.0 (0.0 to 17.6) |
Treatment failure was defined as the receipt of additional standard of care therapy at any time during the study for protocol-defined renal flare, severe extrarenal SLE flare, or suboptimal response.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage of Participants With Treatment Failure | 26.3 (13.4 to 43.1) | 10.5 (1.3 to 33.1) |
A suboptimal response was to be determined in the opinion of the investigator in addition to the following criterion: reproducible proteinuria ≤25% decreased compared to baseline based on UPCR on a 24-hour urine collection performed by a central laboratory.
| percentage of participants | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| LN Cohort: Percentage of Participants With Suboptimal Response | 7.9 (1.7 to 21.4) | 10.5 (1.3 to 33.1) |
For the determination of serum albumin, blood samples were obtained at designated time points.
| grams/liter | LN Cohort: Ravulizumab | LN Cohort: Placebo |
|---|---|---|
| Change at Week 26 | 5.14 ± 5.048 | 6.94 ± 5.252 |
| Change at Week 50 | 6.44 ± 6.761 | 10.65 ± 5.408 |
Partial remission was defined as mean proteinuria \<1 g/24 hours, based on two valid 24-hour urine collections obtained within 2 weeks prior to the study visit.
| percentage of participants | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo |
|---|---|---|
| Week 26 | 26.8 (14.2 to 42.9) | 18.2 (5.2 to 40.3) |
| Week 50 | 39.0 (24.2 to 55.5) | 26.1 (10.2 to 48.4) |
Collected over Baseline up to Week 86. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Evaluation Period: LN Cohort - Ravulizumab | 0/38 (0%) | 6/38 (15.8%) | 28/38 (73.7%) |
| Initial Evaluation Period: LN Cohort - Placebo | 0/19 (0%) | 2/19 (10.5%) | 15/19 (78.9%) |
| Initial Evaluation Period: IgAN Cohort - Ravulizumab | 0/43 (0%) | 1/43 (2.3%) | 17/43 (39.5%) |
| Initial Evaluation Period: IgAN Cohort - Placebo | 0/23 (0%) | 0/23 (0%) | 9/23 (39.1%) |
| Extension Period: LN Cohort - Ravulizumab to Ravulizumab | 0/36 (0%) | 6/36 (16.7%) | 14/36 (38.9%) |
| Extension Period: LN Cohort - Placebo to Placebo | 0/18 (0%) | 2/18 (11.1%) | 16/18 (88.9%) |
| Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab | 0/42 (0%) | 0/42 (0%) | 11/42 (26.2%) |
| Extension Period: IgAN Cohort - Placebo to Ravulizumab | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Event | Initial Evaluation Period: LN Cohort - Ravulizumab | Initial Evaluation Period: LN Cohort - Placebo | Initial Evaluation Period: IgAN Cohort - Ravulizumab | Initial Evaluation Period: IgAN Cohort - Placebo | Extension Period: LN Cohort - Ravulizumab to Ravulizumab | Extension Period: LN Cohort - Placebo to Placebo | Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab | Extension Period: IgAN Cohort - Placebo to Ravulizumab |
|---|---|---|---|---|---|---|---|---|
| Gastroenteritis norovirusInfections and infestations | 0/38 | 1/19 | 0/43 | 0/23 | 0/36 | 1/18 | 0/42 | 0/23 |
| Acute kidney injuryRenal and urinary disorders | 0/38 | 0/19 | 0/43 | 0/23 | 0/36 | 1/18 | 0/42 | 0/23 |
| COVID-19Infections and infestations | 0/38 | 1/19 | 1/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| Cardiac failure acuteCardiac disorders | 0/38 | 1/19 | 0/43 | 0/23 | 0/36 | 0/18 | 0/42 | 0/23 |
| GastroenteritisInfections and infestations | 0/38 | 1/19 | 0/43 | 0/23 | 0/36 | 0/18 | 0/42 | 0/23 |
| NeutropeniaBlood and lymphatic system disorders | 0/38 | 0/19 | 0/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| BronchitisInfections and infestations | 0/38 | 0/19 | 0/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| Epstein-Barr virus infection reactivationInfections and infestations | 0/38 | 0/19 | 0/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| Soft tissue infectionInfections and infestations | 0/38 | 0/19 | 0/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| Urinary tract infectionInfections and infestations | 0/38 | 0/19 | 0/43 | 0/23 | 1/36 | 0/18 | 0/42 | 0/23 |
| Event | Initial Evaluation Period: LN Cohort - Ravulizumab | Initial Evaluation Period: LN Cohort - Placebo | Initial Evaluation Period: IgAN Cohort - Ravulizumab | Initial Evaluation Period: IgAN Cohort - Placebo | Extension Period: LN Cohort - Ravulizumab to Ravulizumab | Extension Period: LN Cohort - Placebo to Placebo | Extension Period: IgAN Cohort - Ravulizumab to Ravulizumab | Extension Period: IgAN Cohort - Placebo to Ravulizumab |
|---|---|---|---|---|---|---|---|---|
| CushingoidEndocrine disorders | 0/38 | 3/19 | 0/43 | 0/23 | 0/36 | 0/18 | 0/42 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 6/38 | 2/19 | 4/43 | 1/23 | 1/36 | 1/18 | 0/42 | 0/23 |
| NauseaGastrointestinal disorders | 6/38 | 2/19 | 1/43 | 2/23 | 0/36 | 1/18 | 0/42 | 0/23 |
| Oedema peripheralGeneral disorders | 3/38 | 3/19 | 0/43 | 2/23 | 0/36 | 0/18 | 0/42 | 0/23 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/38 | 2/19 | 3/43 | 1/23 | 1/36 | 1/18 | 0/42 | 0/23 |
| NasopharyngitisInfections and infestations | 4/38 | 0/19 | 5/43 | 1/23 | 3/36 | 1/18 | 6/42 | 0/23 |
| VomitingGastrointestinal disorders | 5/38 | 1/19 | 0/43 | 0/23 | 1/36 | 1/18 | 0/42 | 0/23 |
| HeadacheNervous system disorders | 5/38 | 2/19 | 0/43 | 0/23 | 3/36 | 1/18 | 3/42 | 0/23 |
| RashSkin and subcutaneous tissue disorders | 5/38 | 1/19 | 0/43 | 3/23 | 0/36 | 0/18 | 0/42 | 0/23 |
| Upper respiratory tract infectionInfections and infestations | 3/38 | 2/19 | 0/43 | 0/23 | 1/36 | 2/18 | 0/42 | 0/23 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of the study intervention.
| Age, Categorical(Participants) | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 18 | 43 | 22 | 121 |
| >=65 years | 0 | 1 | 0 | 1 | 2 |
| Sex: Female, Male(Participants) | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo | Total |
|---|---|---|---|---|---|
| Female | 27 | 15 | 22 | 8 | 72 |
| Male | 11 | 4 | 21 | 15 | 51 |
| Ethnicity (NIH/OMB)(Participants) | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 11 | 3 | 22 |
| Not Hispanic or Latino | 31 | 14 | 27 | 20 | 92 |
| Unknown or Not Reported | 4 | 0 | 5 | 0 | 9 |
| Race/Ethnicity, Customized(Participants) | LN Cohort: Ravulizumab | LN Cohort: Placebo | IgAN Cohort: Ravulizumab | IgAN Cohort: Placebo | Total |
|---|---|---|---|---|---|
| Race — Asian | 13 | 8 | 7 | 7 | 35 |
| Race — Black or African American | 6 | 1 | 0 | 0 | 7 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Race — White | 14 | 5 | 31 | 16 | 66 |
| Race — Asian, White | 1 | 0 | 0 | 0 | 1 |
| Race — Not Reported | 3 | 1 | 4 | 0 | 8 |
| Race — Unknown | 1 | 2 | 0 | 0 | 3 |
| Race — Other | 0 | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Mar 2025, 50 months.
Results were first posted in Jan 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →